9. Total Valuation & Waterfall
LPBI Group Portfolio Valuation
The LPBI Group portfolio represents a mature, debt-free, founder-led collection of intellectual property assets specifically engineered for domain-aware AI in Health. The portfolio is valued conservatively in the high hundreds of millions of dollars, incorporating significant synergistic uplifts from vertical integration, the Composition of Methods (COM) Tool Factory, and the revival potential of the 13 Hidden Gems.
Valuation Breakdown (Key Components)
- Five Primary Trainable Corpuses (Classes I, II, III, V, X)
- 17-part Composition of Methods (COM) – The proprietary Tool Factory and execution infrastructure moat
- 13 Hidden Gems – Each functioning as a ready-made Small Language Model (SLM) foundation
- Four specialized Portals of trainable multimodal data in key medical subspecialties
- 15 Subject Matter Data Sets (“Articles of Note” in leading medical fields)
- Vertical Integration Moat – Cross-pollination across all asset classes
Waterfall Chart The following waterfall chart illustrates the overall composition and build-up of the total portfolio valuation:
[Insert Waterfall Chart 3 – Grand Total Enterprise Value]
Chart 3 – Grand Total Enterprise Value
| Component | Value | % of Grand Total | Key Driver |
| Base Portfolio (Pre-2026, non-COM) | Confidential | Confidential | 10 Digital IP Asset Classes + Intangibles |
| COM Parts 1–9 (Pre-2026) | Confidential | Confidential | Foundational Tool Factory |
| COM Parts 10–17 (2026 & Beyond) | Confidential | Confidential | Advanced layers |
| 13 Hidden Gems Revival | Confidential | Confidential | Revival and spin-off potential |
| Three-Legged Stool Strategy | Confidential | Confidential | AJAUS + SLM + spin-off ecosystem |
| Vertical Integration Moat Premium | Confidential | Confidential | Synergistic effects |
| Founder Bio / Aviva Lev-Ari Contribution | Confidential | Confidential | 14+ years of core IP creation and leadership |
| Subtotal before Adjustment | Confidential | — | — |
| Adjustments (net) | Confidential | — | Conservative balancing adjustment |
| GRAND TOTAL | $650 Million | 100% | Locked conservative midpoint with full synergistic uplift |
Footnote Detailed component valuations are confidential and available only under NDA. The locked enterprise value of the LPBI portfolio is $650 Million. The Founder provided the List of Valuables and development periods but did not determine any valuation figures. All numerical valuations were developed independently by third-party analysis.
Strategic Role in 2026 & Beyond This valuation reflects a high-provenance, causally structured multimodal data moat that is uniquely positioned for Transfer of Ownership. It offers potential acquirers immediate access to one of the only private training corpuses of this depth and quality, capable of powering leadership in AI-driven biomedical discovery.
Additional High-Value Trainable Assets The valuation also incorporates LPBI’s expanding set of specialized trainable assets, including the 15 Subject Matter Small Language Models, dedicated portals (Coronavirus/SARS-CoV-2, Artificial Intelligence in Genomics & Cancer, Cell Therapy & Regenerative Medicine 2026 and Beyond), and other structured multimodal collections. These assets significantly enhance domain-specific performance (particularly for Grok 5) and represent substantial additional upside beyond the base corpus.
While they are part and parcel of the List of Valuables, no itemized valuation for these specific assets is disclosed in the Pre-2026 public valuation summary. Full details are available under appropriate confidentiality agreements.
For additional details, see: Valuation Models per Ten Digital IP Asset Classes in LPBI Group’s Portfolio of IP
Valuation Models per Ten Digital IP Asset Classes in LPBI Group’s Portfolio of IP
2012pharmaceutical
sjwilliamspa